Home/Filings/4/0001062993-24-016894
4//SEC Filing

Blue Horizon Enterprise Ltd 4

Accession 0001062993-24-016894

CIK 0001623526other

Filed

Sep 22, 8:00 PM ET

Accepted

Sep 23, 4:23 PM ET

Size

10.8 KB

Accession

0001062993-24-016894

Insider Transaction Report

Form 4
Period: 2024-09-19
Transactions
  • Sale

    Common Stock

    2024-09-19$14.05/sh1,937,500$27,221,8758,906,181 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2024-09-19$14.05/sh1,937,500$27,221,8758,906,181 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2024-09-19$14.05/sh1,937,500$27,221,8758,906,181 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2024-09-19$14.05/sh1,937,500$27,221,8758,906,181 total(indirect: See Footnote)
Footnotes (1)
  • [F1]Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 4,967,621 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 3,938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein.

Issuer

Stoke Therapeutics, Inc.

CIK 0001623526

Entity typeother
IncorporatedVirgin Islands, British

Related Parties

1
  • filerCIK 0001869057

Filing Metadata

Form type
4
Filed
Sep 22, 8:00 PM ET
Accepted
Sep 23, 4:23 PM ET
Size
10.8 KB